Skip to main content

Table 1 Baseline demographic and clinical characteristics for patients recruited pre- and post- recreational cannabis legalization (N = 1390)

From: Cannabis use in patients treated for opioid use disorder pre- and post-recreational cannabis legalization in Canada

Characteristic Total Sample
(N = 1390)
Recruited pre-legalization
(n = 602)
Recruited post-legalization
(n = 788)
p value
Age in years; mean (SD) 39.3 (10.7) 38.9 (10.4) 39.6 (10.8) 0.295
Male sex; n (%) 817 (58%) 343 (57%) 474 (60.2%) 0.222
Type of MAT; n (%)     0.073
   Methadone 1120 (80.7%) 498 (82.9%) 622 (79%)  
   Buprenorphine 268 (19.3%) 103 (17.1%) 165 (21%)  
Dose (mg/day); median (IQR)
   Methadone 68 (64) 65 (61) 70 (64) 0.276
   Buprenorphine 12 (9.5) 12 (8) 10 (10) 0.097
Length of time in treatment (years); median (IQR) 2 (5.25) 2 (4.9) 2.3 (3.5) 0.756
Opioid abstinencea; n (%) 417 (30%) 176 (29.2%) 241 (30.6%) 0.587
Percentage of opioid-positive urine drug screens amongst non-abstainersa; mean (SD) 22.6 (23.6) 21.1 (23.3) 23.7 (23.8) 0.090
  1. Participant baseline demographic and clinical characteristics
  2. SD standard deviation, MAT medication-assisted treatment, IQR interquartile range
  3. aBased on all urine drug screens collected up to 12 months pre-study entry